Get the Stockscreener App
3.15
1.94%
0.06
Psyence Biomedical Ltd stock is traded at $3.15, with a volume of 34,351.
It is up +1.94% in the last 24 hours and down -31.67% over the past month.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$3.09
Open:
$3.08
24h Volume:
34,351
Relative Volume:
0.01
Market Cap:
$7.22M
Revenue:
-
Net Income/Loss:
$1.52M
P/E Ratio:
-0.4983
EPS:
-6.3213
Net Cash Flow:
$-1.14M
1W Performance:
-9.74%
1M Performance:
-31.67%
6M Performance:
-65.48%
1Y Performance:
-89.76%
1-Day Range:
$2.98
$3.15
1-Week Range:
$2.98
$3.53
52-Week Range:
$0.6254
$74.94
Psyence Biomedical Ltd Stock (PBM) Company Profile
Compare PBM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
3.15 | 7.22M | 0 | 1.52M | -1.14M | -6.3213 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Psyence Biomedical Ltd Stock (PBM) Latest News
Psyence Biomedical Ltd (PBM) Valuation: PE, PB & Fair Value Analysis - TradingKey
PBMWW | Psyence Biomedical Ltd. Warrant Insider Trading - Quiver Quantitative
Psyence Biomedical Ltd (PBM) Institutional Confidence - TradingKey
Psyence Biomedical Ltd (PBM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Psyence Biomedical Ltd (PBM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Psyence Biomedical Ltd (PBM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Psyence Biomedical Ltd (PBMWW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Psyence Biomedical Ltd (PBMWW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Psyence Biomedical Ltd (PBM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Psyence Biomedical Ltd (PBM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Psyence Biomedical Ltd (PBM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Psyence Biomedical Ltd (PBMWW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Psyence Biomedical Ltd (PBMWW) Institutional Confidence - TradingKey
Psyence Biomedical Ltd (PBMWW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PBM News | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
PBMWW Warrants Slide 9.25% as Psyence Biomedical Faces Continued Selling PressureGamma Exposure - newsline.com
PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine - Stocktwits
Jeffrey Weiner holds 59,750 shares in PSYENCE BIOMEDICAL LTD. (PBM) - Stock Titan
Psyence Biomedical Company Profile & Introduction - Moomoo
Psyence Biomedical Corrects Technical Error in 2023 Equity Incentive Plan - TipRanks
Psyence Biomedical (PBM) corrects error in 2023 equity incentive plan - Stock Titan
Psyence Biomedical draws attention premarket after filing on 30% stake - Bez Kabli
Psyence Biomedical (PBM) Surges Over 7%: Bullish Momentum Builds Near ResistanceEnding Diagonal - newsline.com
Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake - TradingView
Psyence Labs gains 30.05% ownership of Psyence Biomedical (PBM) - Stock Titan
Psyence Biomedical Ltd. Warrant (PBMWW) Slides 8.94% as Stock Hovers at $0.03Market Cap Weight - The Legal Advocate
Psyence Biomedical (PBM) Rallies 5.85% as Shares Test Key Resistance Near $4.56Value Area High - The Legal Advocate
Psyence Biomedical Ltd. (PBM) Edges Higher Amid Sector Rotation and Key Technical LevelsUpthrust Pattern - The Legal Advocate
Psyence Biomedical Warrants (PBMWW) Edge Higher; Support and Resistance Converge at $0.03Momentum Breakout Ideas - The Legal Advocate
$Psyence Biomedical (PBM.US)$ picked me up lets goooo - Moomoo
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
PBM Stock Chart | PSYENCE BIOMEDICAL LTD (NASDAQ:PBM) - ChartMill
TradingKey - TradingKey
Is Psyence (PBMWW) stock hiding in plain sight? (+6.50%) 2026-05-08Theta Decay - newser.com
Psyence Biomedical Ltd. Common Shares (PBM) Live Share Price, Invest From India - INDmoney
12 Health Care Stocks Moving In Friday's Pre-Market SessionAkanda (NASDAQ:AKAN), Akari Therapeutics (N - Benzinga
Short sales on the TSX: What bearish investors are betting against - The Globe and Mail
Psyence Biomedical shares rise following equity investment agreement - MSN
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Why is Psyence Biomedical stock falling Wednesday? - MSN
Trending Stocks Today | Psyence Biomedical Soars 130.26% Pre-Market - Moomoo
Psyence Biomedical doses first patient in psilocybin cancer trial By Investing.com - Investing.com Australia
PBM jumps on Trump psychedelic push, ibogaine supply story - MSN
Psyence BioMed Begins Phase IIb Dosing of Psilocybin Candidate NPX-5 in Australian Cancer Adjustment Disorder Trial - TipRanks
Psyence BioMed (Nasdaq: PBM) doses first patient in NPX-5 Phase IIb trial - Stock Titan
Why Is Psyence Biomedical Stock Falling Wednesday? - Sahm
Psyence Biomedical doses first patient in psilocybin cancer trial - Investing.com
Psyence Biomedical (PBM) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Psyence Biomedical Ltd Stock (PBM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):